Novel inhibitory antibody, MAR001, lowers triglycerides and remnant cholesterol in humans
1. ANGPTL4 inhibition decreased triglyceride and remnant cholesterol levels by over 50%. 2. MAR001 was well-tolerated with no significant treatment-related...
Abbreviated MRI is superior to whole-breast ultrasound for detection of cancer in dense breasts
1. Abbreviated MRI detected three times as many invasive cancers compared with ABUS. 2. Contrast-enhanced mammography detected a greater number...
Nivolumab plus ipilimumab improves survival over lenvatinib or sorafenib in liver cancer
1. Median overall survival was 3.1 months greater in the nivolumab plus ipilimumab group. 2. Grade 3-4 treatment-related adverse events...
Early induction of labour reduces shoulder dystocia rates in large for gestational age fetuses
1. Shoulder dystocia was less common in the early induction group compared to standard care. 2. Serious adverse events were...
Obicetrapib and ezetimibe combination therapy lowers LDL cholesterol in high-risk patients
1. FDC obicetrapib plus ezetimibe significantly decreased LDL cholesterol levels by 48.6% compared to placebo. 2. Serious adverse events were...
Semaglutide improves walking ability in patients with peripheral artery disease and type 2 diabetes
1. Maximum walking distance at 52 weeks was significantly improved with semaglutide. 2. There were fewer treatment-related serious adverse events...
Oral gepotidacin is non-inferior to standard therapy for uncomplicated urogenital gonorrhea
1. Gepotidacin was non-inferior to ceftriaxone plus azithromycin for the primary outcome of microbiological success. 2. There were no serious...
Direct oral anticoagulants increase bleeding risk after intracerebral hemorrhage in patients with atrial fibrillation
1. Ischemic stroke occurred less often in patients with atrial fibrillation on DOACs compared to those on placebo. 2. Patients...
Atosiban does not improve neonatal outcomes in threatened preterm births between 30-34 weeks
1. Perinatal mortality and neonatal morbidity were comparable between the atosiban and placebo groups. 2. Maternal adverse events were similar...
Ivonescimab improves survival in advanced non-small cell lung cancer
1. Patients in the ivonescimab group demonstrated a significantly greater progression-free survival than those in the pembrolizumab group. 2. Grade...